The biology research and developλment center
was established×φ
2022
Mar.
Inauguration of the Shanghai Branch★₩γ¥
2022
The Vision
Targeting DNA damage repair patσ'hway to develop anti-cancer age≥♦α•nts
Advantage
Synthetic lethality strategy
Synthetic lethality strategy γ☆÷"allows us to cure cancers wit •↓h mutations on tumor suppr↑≤essor genes. In particular, weγ≠ are able to indirectly tε★π♣arget those “undruggable★ δ” tumor suppressors to drasticall'π¥ y expand the scope of cancer ther✘®α"apeutics. In combination •γwith other types of cancer t&≠herapies, such as tumor immuno÷₽ therapy, our approach also has the♠♣ ↕ potential to overcome cancer d×≤rug resistance caused by secondary$ mutations arising from c£Ω£∑onventional cancer therapies. In sφ→ hort, synthetic lethality strategie★βs specifically kill canc÷↓er cells with a clear biomarker ÷βΩand create a clear pathway for c®δφancer treatment.
Original research conducted in•↑Ω Dr./Professor Yu’s lab has opened a$α new field of DNA damage re'<pair has helped build the foundatio♦★n of the company's "source o★f innovation" on drug dev ₽elopment. We continue to collabo✘ §×rate with well recognized lea↔±↓₹ders in academia and♣↑σ industry to conduct cutti£αng-edge research.
Leadership
Xiaochun YuProfessor
Founder and Chairman
Professor and Associate Dean,♥σ School of Life Sciences, ₩♠≥Westlake University
Professor, University of Mich∑→igan Medical School
M.D., Beijing Medical ¥≥★University; Ph.D, Kurume Univ↑α"♣ersity, Japan
Published more than 1• ♦®00 academic papers
Song LiuPhD
Co-founder and CEO
Executive director of a well-knoγ↑wn healthcare professional investment ₹' fund, invests and manages more tha∏♦n 20 biotechnology compani™<∞←es, many of which have su₹≈€&ccessfully listed in Hong K÷™ong and the US stock markets or ₽±♥completed mergers an∑≥₩d acquisitions
Investigator of Medicinal Chemistry, No↓πvartis Institutes of Biome✘dical Research, small molecule research₽'₽Ω and development on epigenetics
PhD in chemistry, Univer✘"sity of Chicago
Partnerships
We are looking for partners and collaboσφrators on the developm♠ent of anti-tumor therapies.